Drugs / Pfs230D1M-EPA
last change Jul 2020 re-read 2 minutes ago

Pfs230D1M-EPA

Vaccine

Developed for
malaria
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02942277 Oct 2016 → Jul 2020 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Pfs230D1M-EPA ClinicalTrials.gov intervention name — accepted as the source's own label NCT02942277
Modality Vaccine “Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum” NCT02942277